Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 05'th Dec 2025
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
10 AI Stocks Worth Buying Right Now
05:45am, Thursday, 04'th Dec 2025
Artificial intelligence (AI) will reshape industries for decades, making early positioning in focused AI players critical. Smaller AI companies often offer more upside than megacaps that have already
Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a
Recursion Pharmaceuticals, Inc. $RXRX Shares Purchased by Handelsbanken Fonder AB
04:14am, Monday, 01'st Dec 2025
Handelsbanken Fonder AB boosted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) by 20.5% in the undefined quarter, according to the company in its most recent disclosure with
Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade
12:00am, Monday, 01'st Dec 2025
The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $7.25 Average Price Target from Analysts
01:04am, Tuesday, 25'th Nov 2025
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX - Get Free Report) has received an average recommendation of "Hold" from the six ratings firms that are covering the company, Marketbeat Ratings reports.
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?
08:53am, Monday, 24'th Nov 2025
Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript
07:43pm, Friday, 21'st Nov 2025
Recursion Pharmaceuticals, Inc. ( RXRX ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants Christopher Gibson - Co-Founder, CEO & Director Najat Khan - Chi
Is Recursion Pharmaceuticals a Meme Stock?
08:13am, Wednesday, 19'th Nov 2025
Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though.
Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?
10:14am, Tuesday, 18'th Nov 2025
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating
RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y
10:26am, Thursday, 06'th Nov 2025
Recursion Pharmaceuticals narrows its Q3 loss but posts lower-than-expected revenues due to reduced collaboration revenues from its partners.
Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript
08:11pm, Wednesday, 05'th Nov 2025
Recursion Pharmaceuticals, Inc. ( RXRX ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Christopher Gibson - Co-Founder, CEO & Director Najat Khan - Chief R&D Officer, Chief C
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates
08:41am, Wednesday, 05'th Nov 2025
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.34 per share a year ago.
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
06:30am, Wednesday, 05'th Nov 2025
SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and fin
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
06:28am, Wednesday, 05'th Nov 2025
Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President Co-Founder and CEO Chris Gibson to Transition to Chairman of the Bo
